- Conditions
- Myelodysplastic Syndrome, Acute Myelogenous Leukemia
- Interventions
- 5-Azacytidine (5-aza), Valproic Acid, All-Trans Retinoic Acid (ATRA)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 797
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Smoldering Myeloma, Smoldering Multiple Myeloma
- Interventions
- Elotuzumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Hartford, Connecticut • Chicago, Illinois + 5 more
- Conditions
- Melanoma, Metastases
- Interventions
- ABI-007
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Venous Thromboembolism, Cancer
- Interventions
- Tinzaparin sodium
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- CC-98633
- Biological
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 7 more
- Conditions
- Melanoma
- Interventions
- trametinib, nab-paclitaxel
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
- Conditions
- Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Multiple Myeloma
- Interventions
- pomalidomide, marizomib, low-dose dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
- Interventions
- JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
- Biological
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more
- Conditions
- Neuropathy, Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Erythrocyte Transfusion, Beta-Thalassemia
- Interventions
- Luspatercept, Placebo
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
- Conditions
- Carcinoma, Small Cell
- Interventions
- Pomalidomide, Cisplatin, Etoposide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Hershey, Pennsylvania • Dallas, Texas
- Conditions
- Metastatic Breast Cancer
- Interventions
- Amrubicin
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 16
- States / cities
- Jonesboro, Arkansas • Fort Myers, Florida • Gainesville, Georgia + 11 more
- Conditions
- Itch
- Interventions
- Apremilast
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Ixazomib, Pomalidomide, Dexamethasone, Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 4
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- Placebo, Rasigiline, Phenelzine, Ozanimod
- Other · Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Glioblastoma
- Interventions
- CC-90010, Temozolomide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cutaneous T Cell Lymphoma
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- Florida Academic Dermatology Centers
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Interventions
- AVL-292
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 13
- States / cities
- Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 10 more
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- pomalidomide, dexamethasone, rituximab
- Drug
- Lead sponsor
- Steven P. Treon, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab, Etoposide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 13
- States / cities
- Burbank, California • Orlando, Florida • Atlanta, Georgia + 9 more
- Conditions
- Crohn Disease
- Interventions
- Ozanimod, Placebo
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 107
- States / cities
- Peoria, Arizona • North Little Rock, Arkansas • Camarillo, California + 84 more
- Conditions
- Multiple Myeloma
- Interventions
- bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab
- Biological · Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more
- Conditions
- Healthy Volunteers
- Interventions
- [14C]-BMS-986368
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Revlimid (Lenalidomide)
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York